Telehealth Treatment for Opioid Use Disorders

Description

This study aims to use an Opioid Use Disorder (OUD) Telehealth Platform to reduce overdose events. This telehealth platform will be pilot tested to evaluate its preliminary efficacy in terms of motivating engagement in medications for OUD (MOUD), as well as its feasibility, acceptability and satisfaction to both first responders/providers and participants.

Conditions

Opioid Use Disorder

Talk to us

Study Overview

On this page

Study Details

Study overview

This study aims to use an Opioid Use Disorder (OUD) Telehealth Platform to reduce overdose events. This telehealth platform will be pilot tested to evaluate its preliminary efficacy in terms of motivating engagement in medications for OUD (MOUD), as well as its feasibility, acceptability and satisfaction to both first responders/providers and participants.

A Pilot Study of Telehealth Treatment for Opioid Use Disorders

Telehealth Treatment for Opioid Use Disorders

Condition
Opioid Use Disorder
Intervention / Treatment

-

Contacts and Locations

New Haven

Yale School of Medicine, New Haven, Connecticut, United States, 06520

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Can speak, read and write in English
  • * Provision of signed and dated informed consent form
  • * Have a history of at least one opioid overdose
  • * Screened positive for OUD, moderate or severe, based on the Diagnostic and Statistical Manual-5th Edition
  • * Have a working cell phone number and working device that can access a web browser and receive texts (i.e., smartphone, tablet or computer) OR be willing to use a device provided by the study team
  • * Can provide a working email address OR be willing to create one
  • * Current use of buprenorphine, methadone, or naltrexone for a substance use disorder
  • * Pregnancy or lactation
  • * Known current suicide risk based on participant self-report
  • * On parole or incarcerated at time of enrollment based on participant self-report

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Yale University,

Rebekah Heckmann, MD, MPH, MPA, PRINCIPAL_INVESTIGATOR, Yale School of Medicine

Study Record Dates

2024-12-01